Skip to main content
SpringerLink
Log in

Oligometastasierung beim mCRC

Regionale Verfahren bei peritonealer Metastasierung: CRS, HIPEC und PIPAC

  • Gastroonkologie
  • Fortbildung
  • Published:
Im Fokus Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. Klaver YL et al. Peritoneal carcinomatosis of colorectal origin: Incidence, prognosis and treatment options. World J Gastroenterol. 2012;18(39):5489-94

  2. Blaj S et al. Re-operations for early postoperative complications after CRS and HIPEC: indication, timing, procedure and outcome. Langenbeck's Arch Surg. 2019;404(5):541-6

  3. Moran B et al. The results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1200 patients with peritoneal malignancy. Color Dis. 2015;17(9):772-8

  4. Quenet F et al. A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7. J Clin Oncol. 2018;36(suppl_18):LBA3503

  5. Huang C et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for peritoneal carcinomatosis from colorectal cancer: a systematic review and meta-analysis of current evidence. Oncotarget. 2017;8(33):55657-83

  6. Bakkers C et al. Long-term survival after hyperthermic intraperitoneal chemotherapy using mitomycin C or oxaliplatin in colorectal cancer patients with synchronous peritoneal metastases: A nationwide comparative study. Eur J Surg Oncol. 2020;S0748-7983(20):30415-7

  7. Zhang X et al.Oxaliplatin versus mitomycin C in HIPEC for peritoneal metastasis from colorectal cancer: a systematic review and meta-analysis of comparative studies. Int J Colorectal Dis. 2020;https://doi.org/10.1007/s00384-020-03702-y

  8. Glockzin G et al. Perioperative Systemic Chemotherapy, Cytoreductive Surgery, and Hyperthermic Intraperitoneal Chemotherapy in Patients With Colorectal Peritoneal Metastasis: Results of the Prospective Multicenter Phase 2 COMBATAC Trial. Clin Colorectal Cancer. 2018;17(4):285-96

  9. Piso P et al. Benefit of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy in patients with isolated peritoneal metastases from colorectal cancer. Int J Colorectal Dis. 2018;33(11):1559-67

  10. Esquivel J et al. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in the Management of Peritoneal Surface Malignancies of Colonic Origin: A Consensus Statement. Ann Surg Oncol. 2007; 14(1):128-33

  11. Sugarbaker PH, Jablonski KA. Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg. 1995;221(2):124-32

  12. van Oudheusden TR et al. Poor outcome after cytoreductive surgery and HIPEC for colorectal peritoneal carcinomatosis with signet ring cell histology. J Surg Oncol. 2015;111(2): 237-42

  13. Nadiradze G et al. Overcoming Drug Resistance by Taking Advantage of Physical Principles: Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC). Cancers (Basel). 2019;12(1):34

  14. Ellebæk SB et al. Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)-directed treatment of peritoneal metastasis in end-stage colo-rectal cancer patients. Pleura Peritoneum. 2020;5(2):20200109

  15. Magnus P et al. Bidirectional treatment of peritoneal metastasis with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) and systemic chemotherapy: a systematic review. BMC Cancer. 2020;20(1):105

  16. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Kolorektales Karzinom, Langversion 2.1, 2019, AWMF Registrierungsnummer: 021/007OL, http://www.leitlinienprogrammonkologie.de/leitlinien/kolorektales-karzinom/ [abgerufen am: 08.09.2020]

  17. Piso P et al. Morbidity and Mortality Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Data from the DGAV StuDoQ Registry with 2149 Consecutive Patients. Ann Surg Oncol. 2019;26(1):148-54

  18. Alzahrani NA et al. Iterative cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: A multi-institutional experience. Peritoneal Surface Oncology Group International (PSOGI) and Big-RENAPE groups. J Surg Oncol. 2019;119(3):336-46

Download references

Author information

Authors and Affiliations

  1. Krankenhaus Barmherzige Brüder Regensburg, Prüfeninger Straße 86, 93049, Regensburg, Germany

    Pompiliu Piso

  2. München, Germany

    Gabriel Glockzin

Authors
  1. Pompiliu Piso
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gabriel Glockzin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pompiliu Piso.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Piso, P., Glockzin, G. Regionale Verfahren bei peritonealer Metastasierung: CRS, HIPEC und PIPAC. Im Fokus Onkologie 23, 15–19 (2020). https://doi.org/10.1007/s15015-020-2553-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15015-020-2553-5

Search

Navigation